
SEOUL -- Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of an American biotechnology startup, with output scaled up in 2021 pending clearance from health authorities.
Treatment set for clinical trials and mass production next year
SEOUL -- Samsung Biologics has reached an agreement to produce a potential coronavirus treatment on behalf of an American biotechnology startup, with output scaled up in 2021 pending clearance from health authorities.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.